1. Search Result
Search Result
Results for "

MDA

" in MedChemExpress (MCE) Product Catalog:

445

Inhibitors & Agonists

2

Fluorescent Dye

8

Biochemical Assay Reagents

10

Peptides

1

MCE Kits

6

Inhibitory Antibodies

57

Natural
Products

9

Recombinant Proteins

17

Isotope-Labeled Compounds

18

Antibodies

7

Click Chemistry

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15451
    MDA 19
    2 Publications Verification

    Cannabinoid Receptor Neurological Disease
    MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .
    MDA 19
  • HY-15451R

    Reference Standards Cannabinoid Receptor Neurological Disease
    MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .
    MDA 19 (Standard)
  • HY-173083

    Cannabinoid Receptor Neurological Disease
    MDA7 is the selective agonist for cannabinoid receptor 2 with EC50 of 128 nM and 67.4 nM in human CB2 receptor and rat CB2 receptor. MDA7 exhibits good affinity to human CB2 receptor and rat CB2 receptor with Ki of 422 nM and 238 nM. MDA7 exhibits analgesic activity in rats models .
    MDA7
  • HY-173543

    Cannabinoid Receptor Neurological Disease
    MDA-19 N-(5-hydroxyhexyl) is a cannabinoid receptor modulator targeting CB1R/CB2R. MDA-19 N-(5-hydroxyhexyl) is used to study neurological diseases, cancer, and pain regulation .
    MDA-19 N-(5-hydroxyhexyl)
  • HY-113885

    Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    MDA77 is a CB2 inverse agonist with an EC50 of 5.82 nM, showing selectivity for human CB2 and no activity on CB1 .
    MDA77
  • HY-W743300

    Drug Isomer Neurological Disease
    2,3-MDA hydrochloride is a structural isomer of 3,4-Methylenedioxyamphetamine (MDA) which differs only in the placement of the methyledioxy group.
    2,3-MDA hydrochloride
  • HY-W783639S

    5C-MDA-19-d9, Petyl MDA-19-d9

    Isotope-Labeled Compounds Cannabinoid Receptor Neurological Disease
    Bzo-poxizid-d9 (5C-MDA-19-d9, Petyl MDA-19-d9) is deuterium labeled Bzo-poxizid. Bzo-poxizid is a synthetic cannabinoid that is a psychoactive substance .
    Bzo-poxizid-d9
  • HY-139981

    Microtubule/Tubulin Cancer
    Microtubule destabilizing agent-1 (Compound 12b) acts as a microtubule destabilizing agent (MDA) based on hydroxamic acid, could serve as a potential MDA for further investigation. Microtubule destabilizing agent-1 shows favorable metabolism stability, high bioavailability, and potent antitumor activity .
    Microtubule destabilizing agent-1
  • HY-172346

    N-OH MDMA hemioxalate; FLEA hemioxalate

    Drug Derivative Neurological Disease Metabolic Disease
    N-Hydroxy MDMA (N-OH MDMA) hemioxalate is an N-hydroxy analogue of 3,4-methylenedioxymethamphetamine (MDMA). N-Hydroxy MDMA hemioxalate can be rapidly metabolized to MDMA and MDA in rats, which are mainly excreted in urine, and can also be detected in hair .
    N-Hydroxy MDMA hemioxalate
  • HY-160598

    ADC Payload Topoisomerase Cancer
    Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol (compound 45) is a camptothecin compound that can inhibit cell proliferation, with an IC50 of 2.92 ng/mL for MDA‑MB‑468 cells. Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol can be used for the research of cancer .
    Exatecan-amide-bicyclo[1.1.1]pentan-1-ylmethanol
  • HY-115605

    EGFR p38 MAPK ERK Phosphatase Cancer
    CN009543V is an epidermal growth factor receptor (EGFR) agonist. CN009543V enhances tyrosine phosphorylation of EGFR at Tyr1068 and Tyr1173, thereby activating the MAPK/ERK cascade. CN009543V inhibits the activity of PTP-1B in MDA MB468 cells. CN009543V can be used in cancer research .
    CN009543V
  • HY-W275295

    PFDoA

    Reactive Oxygen Species (ROS) Metabolic Disease
    Perfluorododecanoic acid (PFDoA) is a perfluoroalkyl substance (PFAS) found in lake trout. Perfluorododecanoic acid decreases the viability of PC12 cells. Perfluorododecanoic acid also increases reactive oxygen species (ROS), malondialdehyde (MDA) levels and reduces the mitochondrial membrane potential in PC12 cells .
    Perfluorododecanoic acid
  • HY-124894

    Fungal Infection
    (+)-Benalaxyl is a broad-spectrum benzamide fungicide. (+)-Benalaxyl inhibits the growth of the freshwater algae S. obliquus, with an EC50 value of 8.441 mg/L. (+)-Benalaxyl can induce the production of chlorophyll a and b, as well as increase the activity of superoxide dismutase (SOD) and the generation of malondialdehyde (MDA). (+)-Benalaxyl has inhibitory effects on catalase (CAT). (+)-Benalaxyl is effective against diseases caused by oomycetes .
    (+)-Benalaxyl
  • HY-N10965

    Others Cancer
    Gambogic acid B is an active compound. Gambogic acid B can be isolated from the resin of Garcinia hanburyi.. Gambogic acid B has cytotoxicity against A549, HCT116 and MDA MB 231 cells with IC50 values of 1.60 μM, 6.88 μM and 0.87 μM, respectively .
    Gambogic acid B
  • HY-147548

    Reactive Oxygen Species (ROS) Quinone Reductase Others
    Keap1-Nrf2-IN-10 (compound 15) is a potent NQO1 inducer. Keap1-Nrf2-IN-10 inhibits oxidative stress by decreasing the levels of MDA, ROS, NQO1 in the liver for gamma-irradiated mice. Keap1-Nrf2-IN-10 improves the survival of gamma-irradiated mice .
    Keap1-Nrf2-IN-10
  • HY-155158

    Ferroptosis Cancer
    Anticancer agent 147 (compound 6j) is a derivative of sophoridine (HY-N1373) and is a ferroptosis inducer. Anticancer agent 147 can promote the accumulation of intracellular Fe 2+, reactive oxygen species (ROS) and MDA, increase ER stress, and upregulate the expression of the activating transcription factor ATF3. Anticancer agent 147 has good anti-liver cancer effects in vitro and in vivo .
    Anticancer agent 147
  • HY-W754600

    CHM-MDA-19

    Cannabinoid Receptor Others
    BZO-CHMOXIZID is a Cannabinoid-like analog .
    BZO-CHMOXIZID
  • HY-175811

    Ferroptosis Glutathione Peroxidase Cancer
    Ferroptosis inducer-10 is a ferroptosis inducer. Ferroptosis inducer-10 can inhibit A549 cells growth with an IC50 of 0.76 μM. Ferroptosis inducer-10 can deplete GSH, elevate ROS and MDA, and downregulate GPX4 expression. Ferroptosis inducer-10 can induce cell G2/M phase and inhibit migration. Ferroptosis inducer-10 can be used for the research of cancer, such as non-small lung cancer .
    Ferroptosis inducer-10
  • HY-162805

    NO Synthase Topoisomerase Apoptosis NF-κB Inflammation/Immunology Cancer
    iNOS/TopoI-IN-1 (compound AuL9) is a multi-target hybrid molecule with anti-tumor, anti-inflammatory and antioxidant activities. iNOS/TopoI-IN-1 inhibits the growth of breast cancer cells MCF-7 and MDA MB-231 in vitro with IC50 of 3.5 μM and 6.3 μM, respectively, and induces DNA damage and apoptosis of breast cancer cells by inhibiting human topoisomerase I (TopoI) (Ki=2.72 μM). In addition, NOS/TopoI-IN-1 inhibits the expression of iNOS by inhibiting the activation of NF-kB (Ki=1.49 μM) .
    iNOS/TopoI-IN-1
  • HY-N9283

    Reactive Oxygen Species (ROS) Neurological Disease Cancer
    1,2-Diacetoxy-4,7,8-trihydroxy-3-(4-hydroxyphenyl)dibenzofuran, isolated from the edible mushroom Sarcodon leucopus, has antioxidant effects in the DPPH scavenging assay with the IC50 of 28 μM, inhibits malondialdehyde (MDA) with the IC50 of 71 μM, and inhibits α-glucosidase with the IC50 of 6.22 μM .
    1,2-Diacetoxy-4,7,8-trihydroxy-3-(4-hydroxyphenyl)dibenzofuran
  • HY-156247

    SDCBP NF-κB MMP Cancer
    IVMT-Rx-3 is a inhibitor of SDCBP targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis [1]
    IVMT-Rx-3
  • HY-172957

    JAK Cancer
    JNN-5 is a potent and selective JAK2 inhibitor with an IC50 of 0.41 nM. JNN-5 shows strong antiproliferative activities in the TNBC cell lines (MDA-MB-468, MDA-MB-213, HCC70, MDA-MB-157) .
    JNN-5
  • HY-175852

    Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) Cancer
    Ferroptosis inducer-11 is a ferroptosis inducer. Ferroptosis inducer-11 exhibits potent cytotoxicity against HCT-116, NCM-60 and HT-29 cells with IC50 values of 0.43 μM, 3.14 μM and 0.48 μM, respectively. Ferroptosis inducer-11 strongly suppresses GPX4 enzymatic activity with an IC50 of 1.86 μM. Ferroptosis inducer-11 induces ferroptosis, as well as increases intracellular lipid ROS, malondialdehyde (MDA), and Fe 2+ levels, while decreasing glutathione (GSH) levels in colon cancer cells. Ferroptosis inducer-11 can be used for the study of colon cancer .
    Ferroptosis inducer-11
  • HY-W348226

    Drug Derivative Neurological Disease
    MMDPPA is an amphetamine and is a precursor in the synthesis of MDA .
    MMDPPA
  • HY-163897

    PROTACs Ferroptosis Reactive Oxygen Species (ROS) Inflammation/Immunology
    PROTAC NCOA4 degrader-1 is a VHL-based PROTAC NCOA4 degrader. PROTAC NCOA4 degrader-1 is a ferroptosis inhibitor. PROTAC NCOA4 degrader-1 reduces Fe 2+ elevation, ROS production, MDA content and PTGS2 mRNA expression. PROTAC NCOA4 degrader-1 ameliorates liver damage in a CCl4-induced acute liver injury model. PROTAC NCOA4 degrader-1 can be used for the researches of inflammation and immunology. (Pink: NCOA4 ligand (HY-149457). Black: linker (HY-163903). Blue: VHL ligand (HY-138678B)) .
    PROTAC NCOA4 degrader-1
  • HY-77962

    Biochemical Assay Reagents Others
    2-Thiobarbituric acid is a commonly used colorimetric reagent for the detection of malondialdehyde (MDA), a marker of lipid peroxidation. 2-Thiobarbituric acid forms a complex with MDA that can be quantified by colorimetric detection at 532 nm as a measure of lipid peroxidation .
    2-Thiobarbituric acid
  • HY-116447

    Mitochondrial Metabolism Apoptosis Cancer
    Antitumor agent-159 (Compound 13b) targets the mitochondria and downregulates cardiolipin levels. Antitumor agent-159 inhibits the proliferation of cancer cell MDA-MB-231, arrests the cell cycle at sub-G1 phase, and induces apoptosis in MDA-MB-231. Antitumor agent-159 exhibits antitumor efficacy in MDA-MB-231 xenograft mouse models .
    Antitumor agent-159
  • HY-161868

    PARP HDAC Apoptosis Cancer
    DLC-50 is a dual inhibitor for PARP-1 and HDAC-1 with IC50 of 1.2 nM and 31 nM. DLC-50 inhibits the proliferation of cancer cells MDA-MB-436, MDA-MB-231, and MCF-7 with IC50 of 0.3, 2.7 and 2.41 μM. DLC-50 induces apoptosis in MDA-MB-231, arrests the cell cycle at G2 phase .
    DLC-50
  • HY-169054

    TSH Receptor Cancer
    NCATS-SM4420 (Compound A35) is an orally active thyroid-stimulating hormone receptor (TSHR) ligand that inhibits the proliferation of MDA-T32 and MDA-T85 cells in vitro (IC50 values of 0.71 μM and 0.38 μM, respectively) and suppresses metastasis of MDA-T85F1 in mice. NCATS-SM4420 holds promise for research in the field of thyroid cancer .
    NCATS-SM4420
  • HY-162751

    HSP Apoptosis Cancer
    Anticancer agent 249 (Compound 89) is an inhibitor for Hsp90β with IC50 of 16.5 μM in PC3MM2 cell. Anticancer agent 249 inhibits proliferation of cancer cells MCF-7, T47D, MDA-MB-231, MDA-MB-468 and SKBr3 with IC50 of 1.8-5.3 μM. Anticancer agent 249 induces apoptosis in MDA-MB-231. Anticancer agent 249 exhibits antitumor efficacy in mice .
    Anticancer agent 249
  • HY-173075

    RIP kinase Mixed Lineage Kinase Necroptosis Cancer
    Anticancer agent 267 (Compound 5q) is the activator for RIPK3 and MLKL. Anticancer agent 267 inhibits the proliferation in a variety of cancer cell lines (IC50 for MDA-MB-231, MDA-MB-486 and MCF-7 is 9.79, 10.77 and 5.94 μM, respectively), arrests cell cycle at subG1 phase, and induces necroptosis in cell MDA-MB-231. Anticancer agent 267 exhibits antitumor activity in mouse xenograft models .
    Anticancer agent 267
  • HY-B1029
    Danazol
    4 Publications Verification

    PKC Apoptosis Tyrosinase Endocrinology Cancer
    Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC50 of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway .
    Danazol
  • HY-N15759

    Biochemical Assay Reagents Cancer
    8,2'-Diprenylquercetin 3-methyl ether is isolated from Sinopodophyllum hexandrum (Royle) Ying (Sinopodophylli Fructus). 8,2'-Diprenylquercetin 3-methyl ether is cytotoxic to MDA-231 and T47D breast cancer cell lines .
    8,2'-Diprenylquercetin 3-methyl ether
  • HY-B1029R

    Reference Standards Tyrosinase PKC Apoptosis Endocrinology Cancer
    Danazol standard inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC50 of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway .
    Danazol (Standard)
  • HY-10062

    EBP-921

    Akt Farnesyl Transferase Cancer
    AZD3409 is a prenyl inhibitor that exhibits inhibitory activity against both farnesyl transferase and geranylgeranyl transferase I. AZD3409 inhibits the growth of breast cancer cells, with IC50s of 220 nM (MDA-MB-468), 180 nM (MDA-MB-361), and 290 nM (SK-Br-3). AZD3409 significantly reduces the activation level of AKT in breast cancer cell lines. AZD3409 induces G0/G1 phase arrest in MDA-MB-468 cells, causes G2/M phase arrest in MDA-MB-361 cells. AZD3409 can be used for the study of breast cancer .
    AZD3409
  • HY-175030

    HDAC Apoptosis Pyroptosis Necroptosis Cancer
    TNI-97 is a selective and orally active HDAC6 inhibitor, with an IC50 of 0.2 nM. TNI-97 potently inhibited TNBC cell MDA-MB-453 growth and clonogenicity. TNI-97 induces PANoptosis including apoptosis, necroptosis and pyroptosis in MDA-MB-453 cells. TNI-97 shows antitumor activity in the mice carrying the MDA-MB-453 xenograft or carrying murine-derived TNBC cell allografts. TNI-97 can be used for the study of triple-negative breast cancer .
    TNI-97
  • HY-164349

    STAT Cancer
    WZ-2-033 is a potent STAT3 inhibitor. WZ-2-033 inhibits MDA-MB-231, HCC70, and MDA-MB231-4175 cells proliferation, colony survival, migration, and invasion with IC50s of 0.7, 1.3, and 1.3 μM, respectively .
    WZ-2-033
  • HY-152945

    NF-κB Cancer
    Antiproliferative agent-22 (compound 2) is an anticancer agent. Antiproliferative agent-22 shoes anti-proliferative activities against MCF-7, MDA-MB-231 and MDA-MB-468 cells with IC50 values of 6.2 μM, 3.3 μM and 3.3 μM, respectively .
    Antiproliferative agent-22
  • HY-144638

    Apoptosis Cancer
    JMX0293 is an O-alkylamino-tethered salicylamide derivative compound. JMX0293 maintains good potency against MDA-MB-231 cell line (IC50 = 3.38 μM) while exhibiting very low toxicity against human non-tumorigenic breast epithelial cell line MCF-10A (IC50> 60 μM). JMX0293 inhibits STAT3 phosphorylation and contribute to apoptosis in TNBC MDA-MB-231 cells. JMX0293 significantly suppresses MDA-MB-231 xenograft tumor growth in vivo without significant toxicity .
    JMX0293
  • HY-11038B
    Zelavespib hydrochloride
    5+ Cited Publications

    PU-H71 hydrochloride

    HSP Cancer
    Zelavespib (PU-H71) hydrochloride is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.
    Zelavespib hydrochloride
  • HY-11038
    Zelavespib
    5+ Cited Publications

    PU-H71

    HSP Cancer
    Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.
    Zelavespib
  • HY-165600A

    TMB-4

    Cholinesterase (ChE) Others
    Trimedoxime (TMB-4) is a potent reactivator of AChE. Trimedoxime shows potency in inducing oxidative stress, with the IC50 of 22 mM .
    Trimedoxime
  • HY-159990

    Glutathione Peroxidase Cancer
    GPX4-IN-15 (Compound C1) is an inhibitor for GPX4, that inhibits 19.8% GPX4 at 1 μM. GPX4-IN-15 inhibits the proliferation of cancer cell MDA-MB-468, BT-549 and MDA-MB-231 with IC50 of 0.86, 0.96 and 0.48 μM .
    GPX4-IN-15
  • HY-165421

    Mps1 Cancer
    Mps1-IN-10 (Compound 9) is an inhibitor for Mps1 with an IC50 of 6.4 nM. Mps1-IN-10 inhibits the proliferation of cancer cell MDA-MB-231 with a GI50 of 11 nM. Mps1-IN-10 exhibits anti-tumor efficacy in mice MDA-MB-231 xenograft models .
    Mps1-IN-10
  • HY-146203

    FAK Cancer
    Compound 26F not only optimized the effective inhibitory enzyme (ic50= 28.2 nm), but also showed relatively less cytotoxicity (ic50= 3.32 μ M) And induced MDA-MB-231 cell apoptosis in a dose-dependent manner, effectively blocking MDA-MB-231 cells in g0/g1 phase.
    FAK inhibitor 6
  • HY-P10760

    Peptide-Drug Conjugates (PDCs) Cancer
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
    PhAc-ALGP-Dox
  • HY-136747

    Nec2/Hec1 inhibitor

    Drug Derivative Cancer
    N-[4-(2,4-Dimethylphenyl)-2-thiazolyl]-4-pyridinecarboxamide is a derivative of INH1 with anticancer activity. It is cytotoxic to MDA-MB-231, MDA-MB-488, HeLa, and K562 cells (IC50s=1.1, 3.4, 1.6, and 1.2 μM, respectively).
    Nek2/Hec1-IN-1
  • HY-156026

    FAK Cancer
    FAK-IN-11 (Compound 4l) is a FAK inhibitor. FAK-IN-11 binds to the ATP binding pocket of FAK, and inhibits phosphorylation of FAK protein. FAK-IN-11 shows cytotoxic activity against the MDA-MB-231 cells with an IC50 of 13.73? μM. FAK-IN-11 induces non-apoptotic cell death in MDA-MB-231 cells .
    FAK-IN-11
  • HY-149918

    Microtubule/Tubulin Apoptosis Cancer
    Antiproliferative agent-23 is a microtubule-destabilizing agent (MDA) and efficiently disturbes the tubulin-microtubule system. Antiproliferative agent-23 induces apoptosis via a mitochondrion-dependent pathway by downregulating the Bcl-2 protein, upregulating Bax and Cyt c proteins, and activating the caspase cascade. Antiproliferative agent-23 initiates reactive oxygen species (ROS)-mediated endoplasmic reticulum stress in A549/CDDP cells (cisplatin resistant cancer cell line) via the PERK/ATF4/CHOP signaling pathway. Antiproliferative agent-23 has anti-tumor activity .
    Antiproliferative agent-23
  • HY-175497

    ROR Apoptosis Bcl-2 Family PARP Cancer
    ROR1-IN-4 is a selective ROR1 inhibitor with a Kd of 52 nM. ROR1-IN-4 shows potent anti-proliferative activity against TNBC cell line MDA-MB-231 (IC50 = 75 nM). ROR1-IN-4 reduces colony formation, induces apoptosis and inhibits the phosphorylation of ROR1 (Tyr786) in MDA-MB-231 cells. ROR1-IN-4 demonstrates superior anti-tumor efficacy in nude mice bearing MDA-MB-231 subcutaneous xenografts. ROR1-IN-4 can be used for the study of triple-negative breast cancer (TNBC) .
    ROR1-IN-4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: